You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Low-grade central fibroblastic osteosarcoma may be differentiated from its mimicker desmoplastic fibroma by genetic analysis
|
|---|---|
| Published in |
Clinical Sarcoma Research, August 2018
|
| DOI | 10.1186/s13569-018-0104-z |
| Pubmed ID | |
| Authors |
Wangzhao Song, Eva van den Berg, Thomas C. Kwee, Paul C. Jutte, Anne-Marie Cleton-Jansen, Judith V. M. G. Bovée, Albert J. Suurmeijer |
| Abstract |
We studied two cases of rare fibrous bone tumors, namely desmoplastic fibroma (DF) and low-grade central osteosarcoma (LGCOS) resembling desmoplastic fibroma (DF-like LGCOS). As the clinical presentation, imaging features and histopathology of DF and DF-like LGOS show much overlap, the objective of this study was to investigate the value of cytogenetic analysis, molecular pathology and immunohistochemistry in discrimination of these two mimickers. A mutation in CTNNB (S45F) and nuclear beta-catenin immunostaining were observed in DF. DF-LGCOS had amplification of CDK4 and showed strong nuclear expression of CDK4 by IHC. Moreover, the karyotype of DF-LGCOS showed an interstitial heterozygous deletion of the long arm of chromosome 13 (q12q32), associated with loss of the RB1 tumor suppressor gene. Karyotyping and molecular genetic analysis may contribute to a conclusive diagnosis. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 13 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 13 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 2 | 15% |
| Student > Postgraduate | 2 | 15% |
| Other | 1 | 8% |
| Student > Ph. D. Student | 1 | 8% |
| Student > Doctoral Student | 1 | 8% |
| Other | 2 | 15% |
| Unknown | 4 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 6 | 46% |
| Biochemistry, Genetics and Molecular Biology | 2 | 15% |
| Unknown | 5 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 September 2018.
All research outputs
#15,544,609
of 23,102,082 outputs
Outputs from Clinical Sarcoma Research
#58
of 104 outputs
Outputs of similar age
#211,546
of 334,238 outputs
Outputs of similar age from Clinical Sarcoma Research
#3
of 3 outputs
Altmetric has tracked 23,102,082 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 104 research outputs from this source. They receive a mean Attention Score of 3.6. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,238 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one.